Xeomin® 100 Units is a highly purified form of botulinum toxin type A, designed to treat various neuromuscular conditions and aesthetic concerns. Unlike other botulinum toxin products, Xeomin® is free from complexing proteins, which may reduce the risk of antibody development and potential resistance over time.
Key Features:
-
Purity: Xeomin® contains only the active neurotoxin component, eliminating unnecessary proteins.
-
Efficacy: Clinically proven to provide effective results in both therapeutic and aesthetic applications.
-
Stability: Demonstrates stability at room temperature, facilitating storage and handling.
Benefits:
-
Therapeutic Applications:
-
Upper Limb Spasticity: Alleviates muscle stiffness in adults, enhancing mobility and quality of life.
-
Cervical Dystonia: Reduces abnormal head positioning and neck pain associated with this condition.
-
Blepharospasm: Mitigates involuntary eyelid twitching, improving visual function.
-
Chronic Sialorrhea: Decreases excessive salivation in adults, addressing social and hygiene concerns.
-
-
Aesthetic Applications:
- Glabellar Lines: Smooths moderate to severe frown lines between the eyebrows, resulting in a more youthful appearance.
Usage Instructions:
Xeomin® is intended for intramuscular or intraglandular injection and should only be administered by qualified healthcare professionals experienced in the use of botulinum toxin products.
Dosage Recommendations:
-
Chronic Sialorrhea in Adults:
-
Inject into the parotid and submandibular glands bilaterally (four injection sites per session).
-
Total recommended dose: 100 Units per session, divided in a 3:2 ratio between the parotid and submandibular glands.
-
Repeat treatments should be based on clinical need, with intervals of no less than 16 weeks.
-
-
Upper Limb Spasticity in Adults:
-
Dosage varies based on muscle size, number, and location, as well as the severity of spasticity.
-
Maximum total dose: Up to 400 Units per session.
-
Repeat treatments should not occur more frequently than every 12 weeks.
-
-
Cervical Dystonia:
-
Initial recommended dose: 120 Units per session, adjusted based on individual response.
-
Administered into affected neck muscles.
-
Repeat treatments should be based on clinical need, with intervals of no less than 12 weeks.
-
-
Blepharospasm:
-
Initial dosing should consider previous treatments with botulinum toxin.
-
If no prior treatment, a starting dose of 1.25 to 2.5 Units per injection site is recommended.
-
Administered into the orbicularis oculi muscle.
-
Repeat treatments should not occur more frequently than every 12 weeks.
-
-
Glabellar Lines:
-
Total recommended dose: 20 Units per session.
-
Divide into five equal intramuscular injections of 4 Units each: two in each corrugator muscle and one in the procerus muscle.
-
Minimum interval between treatments: 3 months.
-
Safety Considerations:
-
Contraindications:
-
Hypersensitivity to botulinum toxin type A or any excipients in the formulation.
-
Presence of infection at the proposed injection sites.
-
-
Warnings and Precautions:
-
Potential for distant spread of toxin effect, leading to symptoms such as muscle weakness, dysphagia, or respiratory difficulties.
-
Use with caution in patients with pre-existing neuromuscular disorders.
-
Immediate medical attention is required if serious hypersensitivity reactions occur.
-
-
Adverse Reactions:
-
Common side effects include localized pain at the injection site, headache, and muscle weakness.
-
Serious adverse events, though rare, may include dysphagia, respiratory difficulties, and allergic reactions.
-
-
Drug Interactions:
- Caution is advised when used concomitantly with aminoglycosides or other agents that may potentiate the effect of botulinum toxin.
Storage and Handling:
-
Store unopened vials in a refrigerator at 2°C to 8°C.
-
Reconstituted solution should be used within 24 hours and stored under refrigeration.
-
Do not freeze reconstituted solution.
